Market Research Logo

Global Testosterone Replacement Therapy Market 2016-2020

About Testosterone Replacement Therapy

Testosterone replacement therapy, also called androgen replacement therapy, is typically used to treat hypogonadism. Testosterone, a hormone produced by the testes, is responsible for the development of secondary sexual characters in men. The levels of testosterone decrease gradually with age, but sometimes this decline is seen even in young men, leading to a condition known as hypogonadism. This can be treated with external supply of testosterone in the form of gels, patches, injectable, or oral drugs.

Technavio’s analysts forecast the global testosterone replacement therapy market is gradually declining and will post a CAGR of (3.35) % during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global testosterone replacement therapy market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs that treat and prevent hypogonadism.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Testosterone Replacement Therapy Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Allergan
  • Eli Lilly and Company
  • Endo Pharmaceuticals
Other prominent vendors
  • Acerus Pharmaceuticals Corporation
  • Antares Pharma
  • Bayer HealthCare Pharmaceuticals
  • Bedford Labs
  • Clarus Therapeutics
  • Ferring Pharmaceuticals
  • Forendo Pharma
  • Juniper Pharmaceuticals
  • Lipocine
  • MetP Pharma
  • Mylan
  • Pfizer
  • ProStrakan Group
  • Repros Therapeutics
  • Sandoz
  • TesoRx
  • Teva Pharmaceuticals
Market driver
  • Increase in older population
  • For a full, detailed list, view our report
Market challenge
  • FDA warnings on use of testosterone products
  • For a full, detailed list, view our report
Market trend
  • Entry of SARMs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Testosterone Replacement Therapy Market 2016-2020

Technavio recognizes the following companies as the key players in the global testosterone replacement therapy market: AbbVie, Allergan, Eli Lilly, and Endo International.

Other Prominent Vendors in the market are: Acerus Pharmaceuticals, Antares Pharma, Bayer HealthCare Pharmaceuticals, Bedford Labs, Clarus Therapeutics, Ferring Pharmaceuticals, Forendo Pharma, Juniper Pharmaceuticals, Lipocine, MetP Pharma, Mylan, Pfizer, ProStrakan, Repros Therapeutics, Sandoz, TesoRx, and Teva Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “Entry of SARMs will be a key trend for market growth. Testosterone therapies available as injectable or skin delivery formulations are currently used as androgen therapies. However, they are associated with side effects related to fluctuations in testosterone levels. The development and entry of SARMs in the market will serve as a better treatment option for androgen deficiencies. These drugs are available as orally active formulations and target androgen receptors specifically, thus eliciting the desired response in the body.”

According to the report, increase in older population will be a key driver for market growth. Age related lowering of testosterone presents features both primary and secondary hypogonadism. Improved healthcare infrastructure and sophisticated treatment facilities have increased life expectancy of individuals. This has led to an increase in older adult population worldwide.

Further, the report states that generic erosion will be a challenge for the market. The entry of generic drugs in the market results in the decline in the overall market revenue, thus affecting the growth of the market. Though all marketed drugs have not lost their respective patents, generic testosterone formulations are available in the market. The branded versions of the drug costs around $300 – $350 per month and generic versions of testosterone shots can be obtained at as low as $20 per dose. Thus, the generic erosion of drugs acts as a challenge for the growth of the market.



Companies Mentioned

AbbVie, Allergan, Eli Lilly, Endo International, Acerus Pharmaceuticals, Antares Pharma, Bayer HealthCare Pharmaceuticals, Bedford Labs, Clarus Therapeutics, Ferring Pharmaceuticals, Forendo Pharma, Juniper Pharmaceuticals, Lipocine, MetP Pharma, Mylan, Pfizer, ProStrakan, Repros Therapeutics, Sandoz, TesoRx, Teva Pharmaceuticals.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Normal levels of testosterone based on gender
      • Table Normal levels of testosterone at different ages
      • Table Timeline of testosterone replacement therapy products
      • Table Advantages and risks associated with use of testosterone products
  • Hypogonadism
    • Understanding Hypergonadism
    • Pathophysiology
      • Table Causes of hypogonadism
    • Symptoms
      • Table Symptoms of hypogonadism
    • Diagnosis
      • Table Diagnostic algorithm of hypogonadism
    • Treatment
  • Pipeline analysis
    • Table Pipeline portfolio: Global testosterone drugs market
    • TESTAVAN
    • Vibex QST
    • LPCN 1021
    • REXTORO
    • Enclomiphene
    • LPCN 1111
    • TSX-002
    • TEFINA
    • THG-1001
    • MetP Testosterone Nasal Gel
  • Key buying criteria
    • Table Key buying criteria for testosterone replacement therapy
  • Market landscape
    • Global endocrinology drugs market
      • Table Global endocrinology drugs market 2015-2020 ($ billions)
      • Table Market share of global testosterone replacement therapy market in global endocrinology drugs market
    • Global testosterone replacement therapy market
      • Table Global testosterone replacement therapy market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by dosage form
    • Table Global testosterone replacement therapy market by dosage form 2015
    • Gels
    • Injectables
    • Patches
    • Others
  • Geographical segmentation
    • Global testosterone replacement therapy market by geography 2015-2020
      • Table Segmentation of global testosterone replacement therapy market based on geography 2015
      • Table Global testosterone replacement therapy market by geography 2015-2020 ($ billions)
      • Table Global testosterone replacement therapy market by geography 2015-2020
    • Testosterone replacement therapy market in Americas
      • Table Testosterone replacement therapy market in Americas 2015-2020 ($ billions)
      • Table Percentage share of US in testosterone replacement therapy market 2015
    • Testosterone replacement therapy market in EMEA
      • Table Testosterone replacement therapy market in EMEA 2015-2020 ($ billions)
    • Testosterone replacement therapy market in APAC
      • Table Testosterone replacement therapy market in EMEA 2015-2020 ($ billions)
      • Table Global testosterone replacement therapy market: YoY growth and revenue based on geography 2015-2020
  • Market drivers
    • Increase in older population
    • High incidence of testosterone deficiency
    • Rise in chronic diseases
    • Increase in awareness
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Generic erosion
    • FDA warnings on use of testosterone products
    • Adverse effects
    • Physicians are reluctant to prescribe medications with testosterone
    • Reluctance to discuss condition
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Entry of SARMs
    • Support of patient assistance programs
    • Focus on emerging markets
    • Application in new therapeutic indications
  • Vendor landscape
    • Competitive scenario
    • Market analysis 2015
    • AbbVie
      • Table AbbVie: YoY revenue and growth rate of AndroGel 2013-2015 ($ billions)
      • Table AbbVie: Key takeaways
    • Allergan
      • Table Allergan: Key takeaways
    • Eli Lilly
      • Table Eli Lilly: YoY revenue and growth rate of Axiron 2013-2015 ($ millions)
      • Table Geographical segmentation of Axiron by revenue 2015
      • Table Eli Lilly: Key takeaways
    • Endo International
      • Table Endo International: YoY revenue and growth rate of Fortesta 2013-2015 ($ millions)
      • Table Endo: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report